抄録
The utilization of temporary mechanical circulatory support (MCS) in the management of cardiogenic shock is experiencing a notable surge. Acute myocardial infarction remains the predominant etiology of cardiogenic shock, followed by heart failure. Recent findings from the DanGer Shock trial indicate that the percutaneous micro-axial flow pump support, in conjunction with standard care, significantly reduced 6-month mortality in patients with acute myocardial infarction-related cardiogenic shock compared to those receiving standard care alone. However, real-world registry data reveal that the 30-day mortality among patients with acute myocardial infarction-related cardiogenic shock, who received concomitant veno-arterial extracorporeal membrane oxygenation support along with micro-axial flow pump, remain suboptimal. The persistent challenge in the field is how to incorporate, escalate, and de-escalate these temporary MCS to further improve clinical outcomes in such clinical scenarios. This review aims to elucidate the current practices surrounding the escalation and de-escalation of temporary MCS in real-world clinical settings and proposes considerations for future advancements in this critical area.
本文言語 | 英語 |
---|---|
論文番号 | e007924 |
ページ(範囲) | 103-109 |
ページ数 | 7 |
ジャーナル | Journal of Artificial Organs |
巻 | 28 |
号 | 2 |
DOI | |
出版ステータス | 出版済み - 2025/06 |
ASJC Scopus 主題領域
- 医学(その他)
- 生体材料
- 生体医工学
- 循環器および心血管医学